Access practice tools, as well as industry leading news, customizable alerts, dockets, and primary content, including a comprehensive collection of case law, dockets, and regulations. Leverage...
By Tony Dutra
Rohm & Haas Co.'s focus on expert testimony to defend its patents at the Patent Trial and Appeal Board paid off as the federal patent appeals court affirmed Oct. 11 its win over competitor Organik Kimya AS ( Organik Kimya as v. Rohm & Haas Co. , Fed. Cir., No. 2015-2001, 10/11/17 ).
The challenger claimed the patents on polymers useful in coating compositions such as paints were invalid as non-novel and obvious. But Rohm & Haas’s expert conducted experiments to show that the earlier examples of technology Organik Kimya relied on didn’t replicate the patented claims.
The U.S. Court of Appeals for the Federal Circuit dismissed Organik’s complaint that it shouldn’t have to conduct its own experiments to produce contradictory evidence. Experiments aren’t required, but a challenger has to do more than criticize the patent owner’s evidence with labels such as “irrelevant” and “flawed,” the court said.
Rohm, a subsidiary of Dow Chemical Co., sued Organik in federal court for infringement of four patents, including the related U.S. Patent Nos. 6,020,435 and 6,252,004. Organik initiated the PTAB proceedings against the two patents.
The board held separate trials but ultimately ruled in favor of Rohm, relying heavily on the declaration of its expert, Joseph Schork, submitted after trial institution. For example, one of the board’s opinions mentioned Schork’s testimony 22 times.
In general, Organik’s argument depended on getting a broad definition of a “swelling agent” referenced in the patent claims and description. The Federal Circuit agreed with the board and Rohm that the term applied only to an agent that performs specific functions, under specific conditions. Schork’s experiments showed that the prior art lacked an agent suitable for creating the reaction conditions required under the patent claims. Prior art includes examples of earlier patents, patent applications or other documents intended to show the invention was not a new idea.
To rebut that evidence, Organik had to provide “evidence and argument to negate and outweigh the evidence and argument provided by Rohm and Haas,” the court said. Instead, the challenger only leveled “unsupported criticism of Dr. Schork’s methodology,” the court said.
The court also agreed with the PTAB in rejecting Organik’s argument about a grammatical ambiguity in the patent specification of using both the words “include” and “those which” in describing the swelling agent. The term “those which” usually defines a limited set of elements, such that “swelling agent” should be interpreted narrowly, but the word “include” usually refers to a subset, which would support the challenger’s preferred broader interpretation. The court agreed with the board that the term “those which” modified the word “include,” meaning the limited-set definition was correct.
Judge Pauline Newman wrote the court’s opinion, which was joined by Chief Judge Sharon Prost and Judge Richard G. Taranto.
“Dow has steadfastly maintained that Organik’s legal arguments were baseless, and the Court’s decision has now vindicated Dow’s position,” the company said in a statement emailed to Bloomberg BNA. “Dow will remain an innovation leader in the coatings industry by vigorously defending our intellectual property.”
Quinn Emanuel Urquhart & Sullivan LLP represented Rohm & Haas.
Finnegan, Henderson, Farabow, Garrett & Dunner LLP, counsel for Organik Kimya, didn’t immediately respond to Bloomberg BNA’s request for comment.
To contact the reporter on this story: Tony Dutra in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Mike Wilczek at email@example.com
Text available at http://src.bna.com/thp.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)